The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

Pfizer Inc (PFE) stock saw a decline, ending the day at $26.52 which represents a decrease of $-0.39 or -1.45% from the prior close of $26.91. The stock opened at $26.96 and touched a low of $26.42 ...

Pfizer Settles Its Subsidiary’s Kickback Allegations for Nearly $60 Million - Pfizer Inc. agreed to pay over $59,746,277 to ...

Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...

A guide to the people and activist organizations who paved the way for Donald Trump's attacks on diversity practices in ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Pfizer’s Braftovi combo regimen helped prolong the lives of certain patients with previously untreated colorectal cancer, and ...